Wan-Shon Lo

Shon has represented numerous biotech and pharmaceutical companies in patent matters, particularly in litigation arising under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act, but also in patent and regulatory counseling during development of proposed 505(b)(2) and ANDA products.  Her trial experience spans the gamut of IP infringement actions, including trade secret misappropriation and patent, trademark, and copyright infringement in federal district court and before the US International Trade Commission (ITC).

Shon’s matters for branded generic and pharma and biotech companies involve both large and small molecule products, including Xifaxan®, Viltepso®, Hemlibra®, Nexterone®, Actemra®, Avastin®, Dupixent®, Repatha®, Praluent®, Sernivo®, Toviaz®, and Nuvigil®, among others.

Shon is a registered patent attorney and conducts patent and trademark opinion work, counseling, and prosecution. She also conducts due diligence supporting corporate transactions. Shon’s clients and technical proficiency span many industries and sectors, including biotech, pharmaceuticals, medical devices, high-tech, entertainment, food products, consumer products, and household fixtures.

Shon began conducting research as an undergraduate and continued as a research technician and graduate student in various laboratories in the fields of molecular, cellular, and developmental biology and neurobiology at MIT, Stanford, and the University of Chicago. During her prior career as a scientist, Shon co-authored several scientific articles, including an article published in Science magazine.

• Bausch Health in patent litigations brought under the Hatch-Waxman Act, including litigations involving Bausch’s best-selling drug, Xifaxan®
• Bausch Health in litigations arising under the Administrative Procedures Act
• Nippon Shinyaku, a Japanese biopharmaceutical company in a patent infringement suit in the District of Delaware involving antisense oligonucleotide therapies for Duchenne Muscular Dystrophy
• Defended a leading Korean aesthetics product company against trade secret misappropriation and theft/conversion claims in the ITC, an investigation involving issues of first impression at the ITC
• Counseling a US multinational healthcare and medical products company on product development and patent strategy relating to the selection and development of large molecule and small molecule biosimilar, 505(b)(2), and ANDA products
• Advising a pioneer in the field of generative biology on patent matters
• Baxalta Inc. (now Takeda) in a patent infringement suit in the District of Delaware involving Genentech’s market-leading drug Hemlibra®, a bispecific antibody treatment for hemophilia A
• A Chinese biosimilar manufacturer in the BPCIA patent dance
• An American multinational healthcare and medical products company in a license dispute before the American Arbitration Association involving patents and exclusivity under the Hatch-Waxman Act
• Defended an antibody discovery company and its co-founders against claims of trade secret misappropriation case in Massachusetts state court
• Represented a market-leading orthopaedic device manufacturer in a license dispute concerning royalties
• Defended a market-leading orthopaedic device manufacturer in a trade secret misappropriation and unfair competition-based investigation before the ITC involving surgical bone cement
• The biopharmaceutical business of a leading German science and technology company in a license dispute
• Defendant in Promius Pharma LLC v. Perrigo et al.(E.D. Tex.) and Promius Pharma LLC v. Taro Pharmaceuticals Inc. (S.D.N.Y),a district court litigations concerning Sernivo®
• An academic medial hospital and physician-researcher in Immunomedics, Inc. v. Roger Williams Medical Center, et al. (D.N.J.),a district court litigation concerning patent infringement, antitrust, and state law claims relating to an experimental CAR-T cell therapy
• Plaintiff in Jesus Muhammad-Ali v. Final Call, Inc. (N.D. Ill.),a copyright infringement action involving unauthorized distribution of reproductions of plaintiff’s portraits
• Plaintiff in Immunex Corp. v. Sanofi et al. (C.D. Cal.), adistrict court litigation concerning Dupixent®
• Defendant in SwimWays Corp. & Kelsyus LLC v. Bestway (USA), Inc. (E.D. Va.),a district court litigation concerning pool floats
• Plaintiff in Elan Pharma Int’l Ltd. v. Actavis Labs. UT, Inc. (D. Del.), a district court litigation concerning Clindesse®
• Defendant in Pfizer, Inc. & UCB Pharma v. Alkem, Inc., et al. (D. Del.), adistrict court litigation concerning Toviaz®
• Defendant in In re Armodafinil (D. Del.), a district court litigation and also the appeal to the US Circuit Court of Appeals for the Federal Circuit concerning Nuvigil®
• Defendant in Leo Pharma A/S v. Tolmar, Inc. (D. Del.),the district court litigations concerning Dovonex® and Taclonex®
• Defendant in Galderma Labs, LP v. Tolmar, Inc. (N.D. Texas), a district court litigation concerning MetroGel®
• A national chain of photo studios in Picture Me Press v. CPI Corp. (N.D. Ohio), a trademark infringement litigation
• Defendant in Spoilage Cutter Co. v. World Kitchen (N.D. Ill.), a patent infringement and breach of contract litigation